Kardigan, Inc. director Douglas E. Giordano received an equity grant of 20,706 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost to him and represents his entire reported direct holding of 20,706 shares after the transaction.
Each RSU converts into one share of Common Stock upon settlement and is scheduled to vest in full on June 17, 2028, if he remains in continuous service through that date. This filing reflects a routine compensation-related grant rather than an open-market purchase or sale.
Kardigan, Inc.’s Chief Medical Officer Jay Edelberg reported equity-related acquisitions rather than open-market trades. On June 17, 2026, he received 47,784 shares of Common Stock in the form of restricted stock units granted at no cash cost, and a separate transaction shows 61,268 shares of Series B Preferred Stock converting into 97,587 shares of Common Stock in connection with the company’s initial public offering.
The filing also reports 4,459,840 shares of Common Stock held indirectly by Edelberg Family Ventures, LLC, for which he disclaims beneficial ownership except for any pecuniary interest.
Kardigan, Inc. is offering 25,000,000 shares of common stock at an initial public offering price of $16.00 per share, with gross proceeds of $400,000,000 and expected delivery on or about June 22, 2026. The underwriters have a 30‑day option to purchase up to an additional 3,750,000 shares at the IPO price less underwriting discounts and commissions.
The prospectus (dated June 17, 2026) states net proceeds to Kardigan before expenses of $372,000,000, and reserves up to 5% of the offering for directors, officers and certain employees under a directed share program. The prospectus also discloses pro forma common shares outstanding of 64,339,121 shares as of March 31, 2026 and summarizes the company’s clinical-stage cardiovascular pipeline and its Prolaio data platform.
Kardigan, Inc. received an initial insider ownership report from entities affiliated with Perceptive Advisors. The filing shows Perceptive Life Sciences Master Fund Ltd. indirectly holding 5,740,466 shares of common stock and Perceptive Capital Solutions Holdings LP indirectly holding 2,460,195 shares.
The report also lists indirect stock options linked to director compensation for Douglas E. Giordano, covering 80,224 shares at an exercise price of $8.00 per share expiring in 2035 and 33,289 shares at $14.71 per share expiring in 2036. The Perceptive entities and Joseph Edelman each disclaim beneficial ownership except for any indirect pecuniary interest.
Kardigan, Inc. reported initial insider holdings for Chief Financial Officer Jahn Brianne. The Form 3 shows two stock option awards over Kardigan common stock held directly. One option covers 191,136 underlying shares at an exercise price of $14.71 per share, expiring on February 10, 2036. Another option covers 337,285 underlying shares at an exercise price of $8.00 per share, expiring on April 6, 2035. Footnotes state that 25% of each option vests on November 18, 2025 and February 9, 2027, respectively, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.
Kardigan, Inc. director and 10% owner Paul L. Berns filed an initial ownership report detailing his derivative interests in the company. Most of these positions are held indirectly through ARCH Venture Fund XIII, L.P., with additional stock options held directly.
The filing lists a warrant over 876,040 shares of common stock with a $13.42 exercise price and preferred stock series (A, B and B‑1) that are convertible into common shares on a 1.5928-for-1 basis and will automatically convert upon effectiveness of Kardigan’s Form S-1 for its initial public offering. Berns also holds stock options over 33,289 and 80,224 common shares at exercise prices of $14.71 and $8.00, which vest over time and expire in 2036 and 2035, respectively.
Kardigan, Inc. reported the initial holdings of Chief Strategy Officer Andy Pasternak on Form 3. He holds stock options to acquire 358,380 shares of common stock indirectly through The Andrew J. Pasternak Spousal Lifetime Access Trust and 31,339 shares directly, all at an exercise price of $14.71 per share. The options expire on September 30, 2035 and February 9, 2036 and vest over time starting on August 1, 2025 and January 1, 2027, subject to continued service.
Kardigan, Inc.Form 3. The filing lists no transactions, no share holdings, and no derivative positions, so it serves only as a baseline disclosure of his insider status.
Kardigan, Inc. director David P. Meeker reported his existing stock option holdings on Common Stock. The filing lists three option awards: one covering 33,289 underlying shares at an exercise price of $14.7100 per share expiring on February 10, 2036, and two covering 31,856 and 80,224 underlying shares at an exercise price of $8.0000 per share expiring on April 22, 2035 and March 19, 2035, respectively.
Footnotes explain that the shares subject to certain options vest and become exercisable over time, either in three equal annual installments commencing on October 17, 2024 or on a single vesting date of February 9, 2027, in each case conditioned on Meeker’s continued service.
Kardigan, Inc. director Kimberly J. Popovits filed an initial Form 3 reporting her stock option holdings in the company. She holds three direct stock option awards over common stock, with exercise prices of $14.71 and $8.00 per share and expirations in 2035–2036. These options cover 33,289, 31,856, and 80,224 underlying shares. Footnotes state that one grant vests in three equal annual installments beginning September 23, 2024, and another vests fully on February 9, 2027, in each case subject to her continued service.